| Entry |
|
|---|
| Name |
Solifenacin succinate (JAN/USAN/INN);
Vesicare (TN) |
|---|
| Product |
|
|---|
| Generic |
SOLIFENACIN SUCCINATE (AustarPharma LLC), SOLIFENACIN SUCCINATE (AvKARE), SOLIFENACIN SUCCINATE (Golden State Medical Supply), SOLIFENACIN SUCCINATE (Proficient Rx LP), SOLIFENACIN SUCCINATE (Proficient Rx LP), SOLIFENACIN SUCCINATE (Westminster Pharmaceuticals), SOLIFENACIN SUCCINATE (Actavis Pharma), SOLIFENACIN SUCCINATE (Ajanta Pharma Limited), SOLIFENACIN SUCCINATE (Alembic Pharmaceuticals), SOLIFENACIN SUCCINATE (Alembic Pharmaceuticals Limited), SOLIFENACIN SUCCINATE (Amneal Pharmaceuticals NY LLC), SOLIFENACIN SUCCINATE (Apotex Corp.), SOLIFENACIN SUCCINATE (Ascend Laboratories), SOLIFENACIN SUCCINATE (Bryant Ranch Prepack), SOLIFENACIN SUCCINATE (Bryant Ranch Prepack), SOLIFENACIN SUCCINATE (Bryant Ranch Prepack), SOLIFENACIN SUCCINATE (Bryant Ranch Prepack), SOLIFENACIN SUCCINATE (Bryant Ranch Prepack), SOLIFENACIN SUCCINATE (Bryant Ranch Prepack), SOLIFENACIN SUCCINATE (Bryant Ranch Prepack), SOLIFENACIN SUCCINATE (CELLTRION USA), SOLIFENACIN SUCCINATE (Glenmark Pharmaceuticals), SOLIFENACIN SUCCINATE (Golden State Medical Supply), SOLIFENACIN SUCCINATE (Golden State Medical Supply), SOLIFENACIN SUCCINATE (Graviti Pharmaceuticals Private Limited), SOLIFENACIN SUCCINATE (MSN LABORATORIES PRIVATE LIMITED), SOLIFENACIN SUCCINATE (Novadoz Pharmaceuticals LLC), SOLIFENACIN SUCCINATE (Proficient Rx LP), SOLIFENACIN SUCCINATE (Proficient Rx LP), SOLIFENACIN SUCCINATE (Proficient Rx LP), SOLIFENACIN SUCCINATE (Proficient Rx LP), SOLIFENACIN SUCCINATE (Proficient Rx LP), SOLIFENACIN SUCCINATE (REMEDYREPACK), SOLIFENACIN SUCCINATE (ScieGen Pharmaceuticals), SOLIFENACIN SUCCINATE (Unichem Pharmaceuticals (USA)), SOLIFENACIN SUCCINATE (Westminster Pharmaceuticals), SOLIFENACINE SUCCINATE (Cipla USA) |
|---|
| Formula |
C23H26N2O2. C4H6O4
|
|---|
| Exact mass |
480.226
|
|---|
| Mol weight |
480.5528
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Neuropsychiatric agent
DG01491 Muscarinic cholinergic receptor antagonist
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
|
|---|
| Remark |
| Therapeutic category: | 2590 |
| Product (DG00481): | D01269<JP/US> |
|
|---|
| Efficacy |
Overactive bladder agent, Muscarinic acetylcholine receptor antagonist |
|---|
| Comment |
Treatment for relief of symptoms of urinary frequency, urinary urgency, or urge urinary incontinence (UUI) associated with an overactive bladder
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576]
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
G GENITO URINARY SYSTEM AND SEX HORMONES
G04 UROLOGICALS
G04B UROLOGICALS
G04BD Urinary antispasmodics
G04BD08 Solifenacin
D01269 Solifenacin succinate (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Genitourinary Agents
Antispasmodics, Urinary
Solifenacin
D01269 Solifenacin succinate (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
25 Urogenital and anal organ agents
259 Miscellaneous
2590 Miscellaneous
D01269 Solifenacin succinate (JAN/USAN/INN)
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Acetylcholine (muscarinic)
CHRM3
D01269 Solifenacin succinate (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D01269
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D01269
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D01269
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D01269
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 35
1 C6a C 27.3377 -15.6723
2 C1b C 26.1211 -16.3800
3 O6a O 28.5603 -16.3800
4 O6a O 27.3377 -14.2742
5 C1b C 24.9102 -15.6781
6 C6a C 23.6994 -16.3858
7 O6a O 22.4826 -15.6840
8 O6a O 23.6994 -17.7839
9 C1y C 18.3613 -14.7461
10 C1x C 18.3613 -13.3364
11 C1y C 17.1446 -15.4538
12 C1x C 19.5662 -15.4538
13 C1x C 19.0456 -14.5531
14 C1x C 17.8349 -16.6589
15 C1x C 20.2564 -16.6589
16 N1y N 19.0398 -15.9627
17 C1x C 12.3002 -12.6575
18 C1x C 13.5080 -13.3573
19 N1y N 13.5080 -14.7568
20 C1y C 12.3002 -15.4565
21 C8y C 11.0852 -13.3573
22 C8y C 11.0852 -14.7568
23 C8x C 9.8734 -15.4565
24 C8x C 8.6613 -14.7568
25 C8x C 8.6613 -13.3573
26 C8x C 9.8734 -12.6575
27 C8y C 12.3020 -16.8560
28 C8x C 13.5154 -17.5532
29 C8x C 13.5171 -18.9527
30 C8x C 12.3061 -19.6540
31 C8x C 11.0932 -18.9558
32 C8x C 11.0913 -17.5563
33 C7a C 14.7205 -15.4555
34 O7a O 15.9321 -14.7549
35 O6a O 14.7216 -16.8550
BOND 38
1 6 7 1
2 6 8 2
3 1 2 1
4 1 3 1
5 1 4 2
6 2 5 1
7 5 6 1
8 21 17 1
9 17 18 1
10 18 19 1
11 19 20 1
12 20 22 1
13 9 10 1
14 21 22 2
15 22 23 1
16 23 24 2
17 24 25 1
18 25 26 2
19 26 21 1
20 9 11 1
21 20 27 1 #Up
22 9 12 1
23 10 13 1
24 11 14 1
25 12 15 1
26 13 16 1
27 27 28 2
28 28 29 1
29 29 30 2
30 30 31 1
31 31 32 2
32 32 27 1
33 14 16 1
34 19 33 1
35 15 16 1
36 33 34 1
37 33 35 2
38 11 34 1 #Down
|
|---|
|
